India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life Sciences
Awaiting price reaction for this filing.
Sai Life Sciences CFO Sivaramakrishnan Chittor described the current period as a landmark for Indian CDMOs as global pharma diversifies away from China, with India emerging as the preferred alternative after inclusion in the 1260H list. The company is maintaining its 15-20% revenue CAGR guidance and plans to invest between Rs 1,100 crore and Rs 1,300 crore in capacity expansion by FY27, funded through internal accruals and debt. Big pharma contribution to Sai Life Sciences revenue has nearly doubled from 28% to 49% over the past four years, and the firm works with 19 of the top 25 global pharma companies, though commercial benefits from new contracts will take time due to regulatory and product transfer timelines.